Kite, Juno gain on CAR T data at ASCO

Juno Therapeutics Inc. (NASDAQ:JUNO) and Kite Pharma Inc. (NASDAQ:KITE) each posted gains Monday after presenting updated data for their respective chimeric antigen receptor T cell therapies targeting CD19 at the American Society of Clinical Oncology meeting. Both companies hope to seek accelerated approvals of their

Read the full 452 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE